Alnylam Pharmaceuticals ALNY Vutrisiran — Effective interest rate (as percent)
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtInstrumentInterestRateEffectivePercentage.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
The debt obligations to repay Blackstone Life Sciences for the vutrisiran and zilebesiran funding are accreted from the initial carrying amount to the total payment amount using the effective interest rate method over the life of the Development Funding Agreement. The effective interest rate is determined based on the proceeds received and projections of the amounts and timing of the future cash flows. The accretion is recorded as interest expense in the condensed consolidated statements of operations and comprehensive income (loss). We recognize the proceeds received and the principal portion of payments made to Blackstone Life Sciences as financing activities within the condensed consolidated statements of cash flows. As of June 30, 2026 and December 31, 2025, our estimates of total interest expense resulted in an effective annual interest rate of 51% and 46%, respectively, related to vutrisiran and 31% and 32%, respectively, related to zilebesiran.
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's vutrisiran — effective interest rate (as percent)?
- Alnylam Pharmaceuticals (ALNY) reported vutrisiran — effective interest rate (as percent) of 51% in Q2 2026.
- What does vutrisiran — effective interest rate (as percent) mean?
- The actual interest rate incurred on liabilities associated with the product, accounting for the amortization of discounts or premiums. This reflects the true cost of capital for financing arrangements tied to the specific therapeutic asset. A lower rate indicates more efficient financing and lower interest expense burdens.
Ask your AI about Alnylam Pharmaceuticals's vutrisiran — effective interest rate (as percent).
Connect your AI assistant and compare segments, right in your chat.
